Cancer drugs that inhibit CDK7 rapidly shut down pathways responsible for cell proliferation within minutes. For organs to ...

The research shows that novel cancer drugs designed to inhibit CDK7 can, within minutes, shut down gene expression pathways that drive cell proliferation in dozens of different kinds of tissues.

The research shows that novel cancer drugs designed to inhibit CDK7 can, within minutes, shut down gene expression pathways that drive cell proliferation in dozens of different kinds of tissues.

as well as super enhancer targets (CDK7/CDK9) preventing transcription of key oncogenic genes. This therapeutic mechanism entails activation of p53 (an important tumor suppressor) and its ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...

For decades, cancer researchers and pharmaceutical companies have eyed cyclin-dependent kinase (CDK7) with interest due to its role as a "master regulator" of cell proliferation. CDK7 does this in ...

The research shows that novel cancer drugs designed to inhibit CDK7 can, within minutes, shut down gene expression pathways that drive cell proliferation in dozens of different kinds of tissues.